首页 | 本学科首页   官方微博 | 高级检索  
检索        

左西孟旦治疗严重脓毒症及脓毒症休克的临床疗效的Meta分析
引用本文:田文龙,程红颖,董士民.左西孟旦治疗严重脓毒症及脓毒症休克的临床疗效的Meta分析[J].临床荟萃,2018,33(7):562.
作者姓名:田文龙  程红颖  董士民
作者单位:1.天津市武清区人民医院 重症医学科, 天津 301700; 2.河北医科大学第三医院 急诊科, 河北 石家庄 050051
基金项目:河北省医学科学研究重点课题(ZL20140037)
摘    要:目的 采用Meta分析评价左西孟旦在严重脓毒症及脓毒症休克中的疗效,为其在脓毒症中的治疗提供循证医学证据。方法 使用中文和英文数据库,检索左西孟旦治疗严重脓毒症及脓毒症休克的随机对照研究。设定文献纳入和排除标准,对符合标准文献进行质量评定并进行数据提取。应用RevMan 5.3对相关研究的病死率、左心室射血分数(LVEF)、心脏指数(CI) 、肌钙蛋白I(TnI)、乳酸(Lac)、去甲肾上腺素用量进行分析。结果 共纳入13项研究,491例患者,其中左西孟旦组251例,对照组240例。与对照组相比,左西孟旦组的病死率显著降低(RR=0.78,95%CI=0.63~0.96,P=0.02),CI(WMD=0.79, 95%CI=0.56~1.03, P<0.01)、LVEF(WMD=9.03%,95%CI=6.74%~11.31%,P<0.01)显著升高,TnI (WMD=-1.22,95%CI=-1.52~-0.77,P<0.01)、Lac(WMD=-1.41,95%CI=-1.56~-1.27,P<0.01)显著降低,两组去甲肾上腺素用量 (WMD=-0.01,95%CI=-0.03~0.01,P=0.45)差异无统计学意义。结论 与对照组相比,左西孟旦能显著降低严重脓毒症及脓毒症休克患者病死率,降低Lac及TnI的水平,增加CI及LVEF。Meta分析证据支持在严重脓毒症及脓毒症休克中应用左西孟旦。

关 键 词:脓毒症  休克    脓毒性  左西孟旦    Meta分析  

Meta analysis of levosimendan in treatment of severe sepsis and septic shock
Tian Wenlong,Cheng Hongying,Dong Shimin.Meta analysis of levosimendan in treatment of severe sepsis and septic shock[J].Clinical Focus,2018,33(7):562.
Authors:Tian Wenlong  Cheng Hongying  Dong Shimin
Institution:1.Intensive Care Unit, People's Hospital of Wuqing District, Tianjin 301700, China;; 2. Department  of Emergency, the Third Hospital of Hebei Medical University,  Shijiazhuang 050051, China
Abstract:Objective To analyze and evaluate the effect of levosimendan in the treatment of severe sepsis and septic shock through meta analysis, and then to provide evident based evidence for its application in the treatment of sepsis. Methods The CNKI, VIP, Wanfang database, PubMed, EMBASE, Ovidand Cochrane library database were searched for the randomized controlled trials of levosimendan in the treatment of severe sepsis and septic shock from the database inception to October 2015. Meta analysis was conducted on the mortality, the left ventricular ejection fraction (LVEF), the cardiac index (CI), troponin I (TnI), lactate (Lac) and the amount of norepinephrine by using RevMan5.3 software.Results A total of 13 articles involving 491 cases were included, of which 251 cases were in levosimendan group, while the other 240 cases were in the control group. Compared with the control group, the mortality of the patients in the levosimendan group decreased significantly (RR=0.78,95%CI=0.63 0.96,P=0.02). Cardiac index (WMD=0.79, 95%CI=0.56 1.03, P<0.001), LVEF (WMD=9.03%,95%CI=6.74% 11.31%, P<0.00001) of the levosimendan group increased significantly. And the TnI (WMD=-1.22,95%CI=-1.52 -0.77,P<0.00001), lactate (WMD=-1.41,95%CI=-1.56 -1.27,P<0.00001) decreased significantly compared with control group. There was no significant difference in the amount of norepinephrine between the two groups (WMD=-0.01, 95%CI=-0.03 0.01,P=0.45).Conclusion The evidence of meta analysis supports the application of levosimendan in paitents with severe sepsis or septic shock.
Keywords:sepsis  shock  septic  levosimendan  meta analysis  
本文献已被 CNKI 等数据库收录!
点击此处可从《临床荟萃》浏览原始摘要信息
点击此处可从《临床荟萃》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号